BE1014502A5 - Compositions pharmaceutiques. - Google Patents

Compositions pharmaceutiques. Download PDF

Info

Publication number
BE1014502A5
BE1014502A5 BE2001/0779A BE200100779A BE1014502A5 BE 1014502 A5 BE1014502 A5 BE 1014502A5 BE 2001/0779 A BE2001/0779 A BE 2001/0779A BE 200100779 A BE200100779 A BE 200100779A BE 1014502 A5 BE1014502 A5 BE 1014502A5
Authority
BE
Belgium
Prior art keywords
pharmaceutical compositions
oxcarbazúpine
suspension
provides
pharmaceutical composition
Prior art date
Application number
BE2001/0779A
Other languages
English (en)
Inventor
Juergen Sigg
Michael Billington
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10866648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE1014502(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of BE1014502A5 publication Critical patent/BE1014502A5/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

l'invention propose une composition pharmaceutique sous forme d'une suspension comprenant de l'oxcarbazÚpine.
BE2001/0779A 1999-12-20 2001-11-30 Compositions pharmaceutiques. BE1014502A5 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930058.4A GB9930058D0 (en) 1999-12-20 1999-12-20 Organic compounds

Publications (1)

Publication Number Publication Date
BE1014502A5 true BE1014502A5 (fr) 2003-11-04

Family

ID=10866648

Family Applications (2)

Application Number Title Priority Date Filing Date
BE2000/0787A BE1013706A5 (fr) 1999-12-20 2000-12-14 Compositions pharmaceutiques.
BE2001/0779A BE1014502A5 (fr) 1999-12-20 2001-11-30 Compositions pharmaceutiques.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BE2000/0787A BE1013706A5 (fr) 1999-12-20 2000-12-14 Compositions pharmaceutiques.

Country Status (33)

Country Link
US (1) US8119148B2 (fr)
EP (2) EP1437127A1 (fr)
JP (2) JP4588281B2 (fr)
KR (2) KR100496368B1 (fr)
CN (1) CN1216594C (fr)
AR (1) AR030175A1 (fr)
AT (1) ATE269694T1 (fr)
AU (1) AU777619B2 (fr)
BE (2) BE1013706A5 (fr)
BR (1) BR0016524A (fr)
CA (1) CA2390029C (fr)
CO (1) CO5261608A1 (fr)
CZ (1) CZ302737B6 (fr)
DE (1) DE60011809T2 (fr)
DK (1) DK1239832T3 (fr)
ES (1) ES2223641T3 (fr)
FR (1) FR2802423B1 (fr)
GB (1) GB9930058D0 (fr)
HU (1) HU226486B1 (fr)
IL (2) IL149498A0 (fr)
IT (1) ITMI20002717A1 (fr)
MX (1) MXPA02006142A (fr)
MY (1) MY126868A (fr)
NO (1) NO331990B1 (fr)
NZ (1) NZ518755A (fr)
PE (1) PE20010933A1 (fr)
PL (1) PL201331B1 (fr)
PT (1) PT1239832E (fr)
RU (1) RU2277912C2 (fr)
SK (1) SK287553B6 (fr)
TR (2) TR200201459T2 (fr)
WO (1) WO2001045671A2 (fr)
ZA (1) ZA200204863B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
JP4195447B2 (ja) 2002-09-20 2008-12-10 エフ エム シー コーポレーション ミクロ結晶性セルロースを含有する化粧品用組成物
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
WO2005020968A2 (fr) 2003-09-03 2005-03-10 Novartis Ag Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007007182A2 (fr) * 2005-07-08 2007-01-18 Aurobindo Pharma Limited Formes galeniques solides d'agent antiepileptique
EP1906937B1 (fr) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Nouvelle composition de comprimé dispersible
ES2396051T3 (es) * 2006-04-26 2013-02-18 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
CN102612359A (zh) * 2009-09-10 2012-07-25 拜欧波尔特拉及正大有限公司 醋酸艾司利卡西平的口服混悬剂制剂
CN104288104A (zh) * 2014-09-24 2015-01-21 万特制药(海南)有限公司 奥卡西平干混悬剂及其制备方法
EP3397253A1 (fr) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
CN109010322A (zh) * 2018-07-13 2018-12-18 山东达因海洋生物制药股份有限公司 一种包含奥卡西平的口腔分散膜剂及其制备方法
CN115487145B (zh) * 2022-10-10 2023-09-01 上海奥科达医药科技股份有限公司 一种奥卡西平口服混悬液及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289977A1 (fr) * 1987-05-04 1988-11-09 Ciba-Geigy Ag Formes d'administration orale à libération retardée
EP0810216A1 (fr) * 1996-05-27 1997-12-03 Portela & Ca., S.A. Dérivés de 10,11-dihydro-10-oxo-5H-dibenz[b,f]azépine-5-carboxamide

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US4004029A (en) * 1974-05-13 1977-01-18 The Upjohn Company Compositions and method for treating epilepsy and convulsions
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
RO81639A2 (fr) * 1981-02-27 1983-06-01 Intreprinderea De Medicamente "Biofarm",Ro Procede d'obtention d'un poudre suspendable orale d'ampiciline
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
JPS60204713A (ja) 1984-03-30 1985-10-16 Zenyaku Kogyo Kk 水性懸濁組成物
US4693901A (en) * 1985-12-10 1987-09-15 Cardinal Biological, Ltd. Shelf stable dairylike products
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
EP0373103B1 (fr) 1988-11-10 1993-03-31 Ciba-Geigy Ag Formulation orale liquide
GB9102579D0 (en) 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9219524D0 (en) * 1992-09-15 1992-10-28 Smithkline Beecham Plc Novel composition
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
ES2133158T3 (es) * 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
FR2702148B1 (fr) 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2702151B1 (fr) 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2702149B1 (fr) 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
DE4423078B4 (de) * 1994-07-01 2005-01-13 Awd.Pharma Gmbh & Co. Kg Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung
MX9702506A (es) 1994-10-14 1997-07-31 Janssen Pharmaceutica Nv Suspensiones orales de sabeluzol.
DE4443966A1 (de) * 1994-12-09 1996-06-13 Basf Ag Thermoplastische Formmassen
PT101732B (pt) 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
IT1277663B1 (it) 1995-09-28 1997-11-11 Crinos Industria Farmaco Sospensioni acquose stabili di mesalazina per uso topico
IT1286496B1 (it) 1996-11-20 1998-07-15 Leetrim Ltd Dublin Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria
US6037380A (en) * 1997-04-11 2000-03-14 Fmc Corporation Ultra-fine microcrystalline cellulose compositions and process
US6146876A (en) * 1999-06-11 2000-11-14 Millennium Pharmaceuticals, Inc. 22025, a novel human cyclic nucleotide phosphodiesterase
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289977A1 (fr) * 1987-05-04 1988-11-09 Ciba-Geigy Ag Formes d'administration orale à libération retardée
EP0810216A1 (fr) * 1996-05-27 1997-12-03 Portela &amp; Ca., S.A. Dérivés de 10,11-dihydro-10-oxo-5H-dibenz[b,f]azépine-5-carboxamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHICHT S ET AL: "Pharmacokinetics of oxcarbazepine in the dog.", JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, vol. 19, no. 1, 1996, pages 27 - 31, XP000998533, ISSN: 0140-7783 *

Also Published As

Publication number Publication date
HUP0203782A2 (hu) 2003-03-28
IL149498A (en) 2011-05-31
WO2001045671A2 (fr) 2001-06-28
EP1437127A1 (fr) 2004-07-14
IL149498A0 (en) 2002-11-10
HU226486B1 (en) 2009-03-02
CN1216594C (zh) 2005-08-31
ZA200204863B (en) 2003-03-17
RU2002119210A (ru) 2004-02-27
DE60011809D1 (en) 2004-07-29
FR2802423A1 (fr) 2001-06-22
MY126868A (en) 2006-10-31
PT1239832E (pt) 2004-10-29
ITMI20002717A1 (it) 2002-06-15
RU2277912C2 (ru) 2006-06-20
NO20022849D0 (no) 2002-06-14
FR2802423B1 (fr) 2005-03-25
CN1411367A (zh) 2003-04-16
EP1239832A2 (fr) 2002-09-18
WO2001045671A3 (fr) 2002-02-21
MXPA02006142A (es) 2002-12-05
NO20022849L (no) 2002-06-14
JP4588281B2 (ja) 2010-11-24
ES2223641T3 (es) 2005-03-01
PE20010933A1 (es) 2001-09-17
TR200201459T2 (tr) 2002-09-23
DE60011809T2 (de) 2005-06-30
PL355535A1 (en) 2004-05-04
NO331990B1 (no) 2012-05-21
SK8652002A3 (en) 2002-12-03
AU777619B2 (en) 2004-10-21
GB9930058D0 (en) 2000-02-09
SK287553B6 (sk) 2011-01-04
TR200402419T4 (tr) 2004-12-21
ATE269694T1 (de) 2004-07-15
PL201331B1 (pl) 2009-03-31
US8119148B2 (en) 2012-02-21
KR20040098034A (ko) 2004-11-18
DK1239832T3 (da) 2004-08-09
HUP0203782A3 (en) 2005-01-28
JP2003518036A (ja) 2003-06-03
CA2390029A1 (fr) 2001-06-28
KR20020062658A (ko) 2002-07-26
BE1013706A5 (fr) 2002-06-04
KR100496368B1 (ko) 2005-06-21
HK1050474A1 (en) 2003-06-27
EP1239832B1 (fr) 2004-06-23
CO5261608A1 (es) 2003-03-31
NZ518755A (en) 2004-04-30
CA2390029C (fr) 2010-01-26
JP2006312651A (ja) 2006-11-16
CZ302737B6 (cs) 2011-10-12
AU2511801A (en) 2001-07-03
US20030004155A1 (en) 2003-01-02
CZ20022138A3 (cs) 2002-09-11
AR030175A1 (es) 2003-08-13
BR0016524A (pt) 2002-09-24

Similar Documents

Publication Publication Date Title
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
DZ2494A1 (fr) Composition pharmaceutique d&#39;oméprazole.
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26536A1 (fr) Association de compositions pharmaceutiques d&#39;atorvastatine et d&#39;agents antihypertensifs, et procede pour leur preparation.
FR2775596B1 (fr) Nouvelles compositions pharmaceutiques
CA2234282A1 (fr) Complexes medicament/resine stabilises par des chelateurs
RU97118224A (ru) Соединения и композиции для доставки активных агентов
MA26507A1 (fr) Compositions pharmaceutiques d&#39;aerosol
MA26842A1 (fr) Amino-acides bicycliques servant d&#39;agents pharmaceutiques
CA2163706A1 (fr) Derives amino-acides de paclitaxel
BR9810495A (pt) Composição farmacêutica
ATE231872T1 (de) Thiazolopyrimidinderivate
IT1295645B1 (it) Apparecchio per l&#39;elettroemanazione di principi attivi.
CA2361402A1 (fr) Bis-sulfonamides
BG105256A (en) Muscarinic agonists and antagonists
MY135916A (en) Use of certain affinity nmda antagonists as antidepressants
ZA989997B (en) Compositions of lipid lowering agents.
MY126868A (en) Suspension comprising oxcarbazepine
CA2152771A1 (fr) Derives 7-o-ether de taxane
FR2792529B1 (fr) Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DK0977871T3 (da) Neurotrypsin
FR2779145B1 (fr) Nouvelles compositions pharmaceutiques

Legal Events

Date Code Title Description
MK Patent expired because of reaching the maximum lifetime of a patent

Effective date: 20201214